The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Open accessAbstract
The motor symptoms of Parkinson’s disease (PD) are due to the progressive loss of dopamine (DA) neurons in substantia nigra pars compacta (SNc). Nothing is known to slow the progression of the disease, making the identification of potential neuroprotective agents of great clinical importance. Previous studies using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD have shown that antagonism of L-type Ca2+ channels protects SNc DA neurons. However, this was not true in a 6-hydroxydopamine (6-OHDA) model. One potential explanation for this discrepancy is that protection in the 6-OHDA model requires greater antagonism of Cav1.3 L-type Ca2+ channels thought to underlie vulnerability and this was not achievable with the low affinity dihydropyridine (DHP) antagonist used. To test this hypothesis, the DHP with the highest affinity for Cav1.3 L-type channels – isradipine – was systemically administered and then the DA toxin 6-OHDA injected intrastriatally. Twenty-five days later, neuroprotection and plasma concentration of isradipine were determined. This analysis revealed that isradipine produced a dose-dependent sparing of DA fibers and cell bodies at concentrations achievable in humans, suggesting that isradipine is a potentially viable neuroprotective agent for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,417
The efficiency of systematic sampling in stereology and its prediction*
Gundersen, H. J. G., & Jensen, E. B. (1987) · Journal of Microscopy · doi:10.1111/j.1365-2818.1987.tb02837.x · Cited by 3,520
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Self-citationOxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Self-citationMcCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D. A., & Di Monte, D. A. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0507 · Cited by 838
Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state.
Bean, B. P. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.20.6388 · Cited by 824
Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 803
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739
Kirik, D., Rosenblad, C., & Björklund, A. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6848 · Cited by 663
Riederer, P., & Wuketich, S. (1976) · Journal of Neural Transmission · doi:10.1007/bf01249445 · Cited by 577
Targeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
Oorschot, D. E. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960318)366:4<580::aid-cne3>3.0.co;2-0 · Cited by 499
Tatton, N. A., & Kish, S. J. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00545-3 · Cited by 468
Histochemical detection of apoptosis in Parkinson's disease
Mochizuki, H., Goto, K., Mori, H., & Mizuno, Y. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00336-z · Cited by 452
Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S. J., & Przedborski, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633998 · Cited by 372
Neuronal Calcium Homeostasis and Dysregulation
Gleichmann, M., & Mattson, M. P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3386 · Cited by 360
MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease
Przedborski, S., Tieu, K., Perier, C., & Vila, M. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041771.66775.d5 · Cited by 287
L‐type calcium channel blockers and Parkinson disease in Denmark
Ritz, B., Rhodes, S. L., Qian, L., Schernhammer, E., Olsen, J. H., & Friis, S. (2010) · Annals of Neurology · doi:10.1002/ana.21937 · Cited by 273
Khaliq, Z. M., & Bean, B. P. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0143-10.2010 · Cited by 261
Use of antihypertensives and the risk of Parkinson disease
Becker, C., Jick, S. S., & Meier, C. R. (2008) · Neurology · doi:10.1212/01.wnl.0000303818.38960.44 · Cited by 230
Expression and 1,4-Dihydropyridine-Binding Properties of Brain L-Type Calcium Channel Isoforms
Sinnegger-Brauns, M. J., Huber, I. G., Koschak, A., Wild, C., Obermair, G. J., Einzinger, U., Hoda, J.-C., Sartori, S. B., & Striessnig, J. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.049981 · Cited by 212
Calcium channel blockers: an update
Eisenberg, M. J., Brox, A., & Bestawros, A. N. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.027 · Cited by 187
Anekonda, T. S., Quinn, J. F., Harris, C., Frahler, K., Wadsworth, T. L., & Woltjer, R. L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.020 · Cited by 155
The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic Strategies
Surmeier, D. J., Guzmán, J. N., Sánchez-Padilla, J., & Goldberg, J. A. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3521 · Cited by 142
Self-citationKupsch, A. R., Sautter, J., Schwarz, J., Riederer, P. F., Gerlach, M., & Oertel, W. H. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00917-1 · Cited by 110
Fitton, A., & Benfield, P. (1990) · Drugs · doi:10.2165/00003495-199040010-00004 · Cited by 94
Schuster, S., Doudnikoff, É., Ottosson, D. R., Berthet, A., Aubert, I., Ittrich, C., Bloch, B., Cenci, M. A., Surmeier, D. J., Hengerer, B., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.008 · Cited by 92
Self-citationBonci, A., Grillner, P., Mercuri, N. B., & Bernardi, G. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-17-06693.1998 · Cited by 89
Kupsch, A. R., Gerlach, M., Pupeter, S. C., Sautter, J., Dirr, A., Arnold, G., Opitz, W., Przuntek, H., Riederer, P. F., & Oertel, W. H. (1995) · Neuroreport · doi:10.1097/00001756-199503000-00009 · Cited by 87
Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
Simuni, T., Borushko, E., Avram, M. J., Miskevics, S. A., Martel, A., Zadikoff, C., Videnović, A., Weaver, F. M., Williams, K., & Surmeier, D. J. (2010) · Movement Disorders · doi:10.1002/mds.23308 · Cited by 64
Self-citationBean, B. P. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb24113.x · Cited by 42
Calcium channel blocker use and risk of Parkinson's disease
Simon, K. C., Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2010) · Movement Disorders · doi:10.1002/mds.23191 · Cited by 42
Park, J., Park, Y., Rhim, S., Jhee, O., Kim, S., Yang, S.-C., Lee, M., Shaw, L. M. J., & Kang, J. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.11.021 · Cited by 23
Sautter, J., Kupsch, A., Earl, C. D., & Oertel, W. H. (1997) · Experimental Brain Research · doi:10.1007/s002210050204 · Cited by 18
Cited by
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Self-citationZamponi, G. W., Striessnig, J., Koschak, A., & Dolphin, A. C. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009654 · Cited by 1,103
Disruption of mitochondrial complex I induces progressive parkinsonism
González-Rodríguez, P., Zampese, E., Stout, K. A., Guzman, J. N., Ilijic, E., Yang, B., Tkatch, T., Stavarache, M. A., Wokosin, D. L., Gao, L., et al. (2021) · Nature · doi:10.1038/s41586-021-04059-0 · Cited by 546
Self-citationPacelli, C., Giguère, N., Bourque, M.-J., Lévesque, M., Slack, R. S., & Trudeau, L.-É. (2015) · Current Biology · doi:10.1016/j.cub.2015.07.050 · Cited by 530
A Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Metadata
- Authors
- Ilijic, E., Guzman, J. N., & Surmeier, D. J.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 43
- Issue
- 2
- Pages
- 364-371
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2010680034
- Cited by
- 259
- References
- 37
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.